The National Times - Airbus ready to build two new European fighter jets if 'customers' ask

Airbus ready to build two new European fighter jets if 'customers' ask


Airbus ready to build two new European fighter jets if 'customers' ask
Airbus ready to build two new European fighter jets if 'customers' ask / Photo: © AFP

Airbus, which represents Germany and Spain in the multibillion-euro FCAS warplane programme, will support a proposal to instead build two separate jets if the countries participating in the project request it, chief executive Guillaume Faury said Thursday.

Change text size:

"If mandated by our customers, we would support a two-factor solution and are committed to playing a leading role," Faury told a news conference.

"But the deadlock of a single pillar should not jeopardise the entire future of this high-tech European capability which will bolster our collective defence," he said.

The Future Combat Air System (FCAS) programme was launched in 2017 to replace France's Rafale jet and the Eurofighter planes used by Germany and Spain.

But the scheme, jointly developed by the three countries, has stalled as disagreements persist between Dassault and Airbus.

On Wednesday, German Chancellor Friedrich Merz signalled that Berlin could abandon the project, saying Germany does not need the same type of fighter jets as France.

Failure to get FCAS off the ground would be a blow to broader efforts by European NATO allies to demonstrate tight defence cooperation in the face of threats from Russia and doubts about American security commitments.

German industrial interests and some politicians have bristled at Dassault's alleged efforts to revise FCAS agreements and take greater control of the aircraft portion of the project.

In September 2025, the head of Dassault Aviation, Eric Trappier, said his firm could build the future European fighter jet by itself.

"I don't mind if the Germans are complaining. If they want to do it on their own, let them do it on their own," he said at the time.

Faury said Thursday that Airbus believed the program "as a whole makes sense".

"We've spent a lot of time and energy to support this program that has a number of pillars," he said.

However, "On the next-generation fighter, there is a deadlock that is linked to expectations of the governance that differ between partners on what leadership means, what cooperation means."

He said he other aspects of FCAS, such as an interlinked drone swarm and a digital cloud communication system, were "making good progress".

- 'Incomprehensible' -

Faury said that if a two‑fighter‑jet solution were possible, it could be an opportunity for other partners to join the programme.

"But it belongs to our customers to decide with whom they want to join forces," he added.

Analysts estimate it will cost 100 billion euros ($118 billion) to develop the new jet and its cutting-edge technologies.

French President Emmanuel Macron's office said Wednesday that he remained "committed to the success of the FCAS project" and considered it "incomprehensible" that the disagreements have not been overcome at a time when Europe must "show unity and performance".

Spain said Thursday that it remained committed to the development of the European combat aircraft.

In a brief statement responding to questions from AFP, Spain's defence ministry said the country "remains fully committed to the program based on the principles established by the countries (Germany, France, Spain)" in the framework agreement signed in 2019.

A.M.James--TNT

Featured

Carney touts Canada 'pivot' away from US as tariffs rise

Canadian Prime Minister Mark Carney on Tuesday said reducing economic ties with the United States would come at a cost but the long-term benefits were clear, as retaliatory tariffs on US products took effect.

The "Everlasting Battery" Inside Your Joints:UConn Professor's Self-Powered Healing Material just Got Acquired

A material that turns your own movement into medicine has just landed a corporate home. PetVivo Holdings (OTCQX: PETV), a veterinary biotech and biomedical device company focused on treating osteoarthritis in dogs and horses, has acquired PiezoBioMembrane (PBM) — a startup built around a biodegradable implant that generates electricity from the everyday force of a joint in motion, and uses that charge to help regrow cartilage from the inside out. The material is the invention of Thanh Nguyen, a professor of mechanical engineering in UConn's College of Engineering, who founded PBM in 2021 to advance new implementation methods for his work with piezoelectric materials — substances that convert mechanical force into electrical energy. These materials are typically ceramics: hard, brittle, and poorly suited for medical use. But Nguyen's lab developed new forms that are so , flexible, and biodegradable, breaking down naturally within the body over time. wound healing, The materials have already shown strong potential across a range of medical applications, including tissue regeneration, implanted force sensors, and targeted drug delivery in tumor treatment. How It Works biodegradable ultrasound for In the case of arthritis, Nguyen explains, the piezoelectric materials function as an off-the-shelf product that can be implanted or injected directly into the ailing joint — with no drugs, chemicals, or cells required. The everyday force exerted on the joint generates a small electrical charge, which helps regrow healthy cartilage, mimicking the body's natural use of electricity to regenerate tissue. "The body can be electrically stimulated to regrow," Nguyen says. PBM's materials "act like a battery — an everlasting battery that works whenever there is a force applied, and vanishes safely inside the body over time." PetVivo's Vision for the Acquisition PetVivo Holdings CEO John Lai expressed enthusiasm for the merger's potential to improve the lives of companion animals globally. "PBM has developed a compelling functional biomaterials platform with the potential to support the development of multiple medical device and therapeutic product lines across both human and animal health markets," Lai said in a press release. "By combining PBM's scientific innovation with PetVivo's product development capabilities, commercialization experience, regulatory expertise, and public company infrastructure, we believe we can accelerate theadvancement of technologies that may serve as the foundation for numerous future products and strategic opportunities." For Nguyen, the deal is a chance to scale technology that could eventually benefit both animals and people. "PetVivo is an animal health company, but they do have a big passion: pushing the technology towards clinical trials for human use," Nguyen says. "That aligned perfectly with my passion for developing technology that has an impact on human life. That is why I am excited about this merger, which facilitates my passion." A Track Record of Innovation Nguyen's research sits at the intersection of medicine, micro/nanotechnology, and biomaterials. His inventions have earned him publications in prominent scientific journals and media coverage from outlets including NPR. Nguyen founded PBM during the COVID-19 pandemic, a er realizing the material he had developed could be used to create an especially effective, biodegradable face mask — one where the mechanical force of breathing generated an electrical charge that provided an extra layer of protection against viruses. PBM is not Nguyen's only venture in the acquisition pipeline. His other startup, Single-Time Microneedles (STM), is also currently undergoing an acquisition process. STM has pioneered stable, efficient vaccine delivery technology in the form of an adhesive patch. shelfNguyen's focus on biodegradable materials has translated into a remarkably diverse range of medical applications. He has received five R01 grants from the National Institutes of Health (NIH) supporting research in cartilage regeneration, bone regeneration, HIV antibody delivery systems, and biodegradable ultrasound technology to boost the effectiveness of chemotherapy for brain cancer. "Whatever we are working on, we want to show that it works very well in vitro and in vivo," Nguyen says. "Then, when we are at the point of commercialization, we set up a startup or license the technology — or maybe team up with an industry partner." Thanh Nguyen is a professor of mechanical engineering in UConn's College of Engineering. (Courtesy of Thanh Nguyen

Octrado introduces its proprietary trading offering: "Your Skill. Our Capital"

Infrastructure, transparent rules and clear legal boundaries positioned as the core of the funded-account model

Could gas prices return to 2022 highs on US-Iran war?

European gas prices have more than doubled owing to the US-Iran war, just as Europe needs to replenish its reserves ahead of winter.

Change text size: